Incidence of type 2 diabetes mellitus in persons living with HIV initiated on dolutegravir-based antiretroviral regimen in Ghana: an observational longitudinal study
Abstract Background Few studies have reported hyperglycemia and diabetic ketoacidosis in patients on dolutegravir (DTG) treatment. This study determined the effect of DTG on fasting blood glucose levels in a cohort of persons living with HIV (PLHIV) in Ghana and initiating DTG regimens. Methods A tw...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-11-01
|
| Series: | Journal of Health, Population and Nutrition |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s41043-024-00695-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850216052675313664 |
|---|---|
| author | Margaret Lartey Ernest Kenu Vincent Ganu Stephen Ayisi Addo Kofi Agyabeng Delia Bandoh Marijanatu Abdulai Prince Tsekpetse Kwasi Torpey |
| author_facet | Margaret Lartey Ernest Kenu Vincent Ganu Stephen Ayisi Addo Kofi Agyabeng Delia Bandoh Marijanatu Abdulai Prince Tsekpetse Kwasi Torpey |
| author_sort | Margaret Lartey |
| collection | DOAJ |
| description | Abstract Background Few studies have reported hyperglycemia and diabetic ketoacidosis in patients on dolutegravir (DTG) treatment. This study determined the effect of DTG on fasting blood glucose levels in a cohort of persons living with HIV (PLHIV) in Ghana and initiating DTG regimens. Methods A two-year observational longitudinal cohort study conducted from 12th October 2020 to 31st December 2022. Fasting blood glucose was measured at baseline, 12, 24, 36 and 72 weeks for patients after a 12 h overnight fast. The Kaplan-Meier estimator was used to estimate the risk of developing type 2 diabetes mellitus (T2DM). Cox proportional hazard model was used in estimating hazard ratios. Results A total of 1334 non-diabetic patients were enrolled with 78% (1039) females and 83% (1104) were antiretroviral therapy experienced. The incidence proportion and rate of T2DM at 72 weeks were 11.8% (95%CI: 10.2–13.7) and 98.1 cases per 1000 PY (95%CI: 83.9-114.6) respectively. The median time to development of T2DM was 24 weeks post DTG initiation. Male sex (aHR 2.9 [95%CI: 1.9–4.3]), abnormal waist-hip ratio (1.67 [95% CI: 1.15–2.43]) and abnormal total serum cholesterol (aHR 1.6 [95%CI: 1.1–2.3]) were found to be significant determinants of T2DM. Conclusion Incidence of T2DM is high among non-diabetic PLHIV within 72 weeks of initiating DTG based therapy with males having a higher risk. Longitudinal changes in waist-hip ratio and serum cholesterol among patients initiated on DTG needs to be monitored regularly. |
| format | Article |
| id | doaj-art-0f94b3ab54ed4cbdb31a43d741b25994 |
| institution | OA Journals |
| issn | 2072-1315 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Health, Population and Nutrition |
| spelling | doaj-art-0f94b3ab54ed4cbdb31a43d741b259942025-08-20T02:08:25ZengBMCJournal of Health, Population and Nutrition2072-13152024-11-0143111010.1186/s41043-024-00695-0Incidence of type 2 diabetes mellitus in persons living with HIV initiated on dolutegravir-based antiretroviral regimen in Ghana: an observational longitudinal studyMargaret Lartey0Ernest Kenu1Vincent Ganu2Stephen Ayisi Addo3Kofi Agyabeng4Delia Bandoh5Marijanatu Abdulai6Prince Tsekpetse7Kwasi Torpey8Department of Medicine & Therapeutics, University of Ghana Medical SchoolGhana Field Epidemiology and Laboratory Training Programme, Department of Epidemiology and Disease Control, School of Public Health, University of GhanaDepartment of Medicine, Korle Bu Teaching HospitalNational AIDS/STI Control Programme, Ghana Health ServiceDepartment of Biostatistics, School of Public Health, University of GhanaGhana Field Epidemiology and Laboratory Training Programme, Department of Epidemiology and Disease Control, School of Public Health, University of GhanaNational AIDS/STI Control Programme, Ghana Health ServiceGhana Field Epidemiology and Laboratory Training Programme, Department of Epidemiology and Disease Control, School of Public Health, University of GhanaDepartment of Population, Family, Reproductive Health, School of Public Health, University of GhanaAbstract Background Few studies have reported hyperglycemia and diabetic ketoacidosis in patients on dolutegravir (DTG) treatment. This study determined the effect of DTG on fasting blood glucose levels in a cohort of persons living with HIV (PLHIV) in Ghana and initiating DTG regimens. Methods A two-year observational longitudinal cohort study conducted from 12th October 2020 to 31st December 2022. Fasting blood glucose was measured at baseline, 12, 24, 36 and 72 weeks for patients after a 12 h overnight fast. The Kaplan-Meier estimator was used to estimate the risk of developing type 2 diabetes mellitus (T2DM). Cox proportional hazard model was used in estimating hazard ratios. Results A total of 1334 non-diabetic patients were enrolled with 78% (1039) females and 83% (1104) were antiretroviral therapy experienced. The incidence proportion and rate of T2DM at 72 weeks were 11.8% (95%CI: 10.2–13.7) and 98.1 cases per 1000 PY (95%CI: 83.9-114.6) respectively. The median time to development of T2DM was 24 weeks post DTG initiation. Male sex (aHR 2.9 [95%CI: 1.9–4.3]), abnormal waist-hip ratio (1.67 [95% CI: 1.15–2.43]) and abnormal total serum cholesterol (aHR 1.6 [95%CI: 1.1–2.3]) were found to be significant determinants of T2DM. Conclusion Incidence of T2DM is high among non-diabetic PLHIV within 72 weeks of initiating DTG based therapy with males having a higher risk. Longitudinal changes in waist-hip ratio and serum cholesterol among patients initiated on DTG needs to be monitored regularly.https://doi.org/10.1186/s41043-024-00695-0DolutegravirType 2 diabetes mellitusSub-Saharan AfricaARTCohort studies |
| spellingShingle | Margaret Lartey Ernest Kenu Vincent Ganu Stephen Ayisi Addo Kofi Agyabeng Delia Bandoh Marijanatu Abdulai Prince Tsekpetse Kwasi Torpey Incidence of type 2 diabetes mellitus in persons living with HIV initiated on dolutegravir-based antiretroviral regimen in Ghana: an observational longitudinal study Journal of Health, Population and Nutrition Dolutegravir Type 2 diabetes mellitus Sub-Saharan Africa ART Cohort studies |
| title | Incidence of type 2 diabetes mellitus in persons living with HIV initiated on dolutegravir-based antiretroviral regimen in Ghana: an observational longitudinal study |
| title_full | Incidence of type 2 diabetes mellitus in persons living with HIV initiated on dolutegravir-based antiretroviral regimen in Ghana: an observational longitudinal study |
| title_fullStr | Incidence of type 2 diabetes mellitus in persons living with HIV initiated on dolutegravir-based antiretroviral regimen in Ghana: an observational longitudinal study |
| title_full_unstemmed | Incidence of type 2 diabetes mellitus in persons living with HIV initiated on dolutegravir-based antiretroviral regimen in Ghana: an observational longitudinal study |
| title_short | Incidence of type 2 diabetes mellitus in persons living with HIV initiated on dolutegravir-based antiretroviral regimen in Ghana: an observational longitudinal study |
| title_sort | incidence of type 2 diabetes mellitus in persons living with hiv initiated on dolutegravir based antiretroviral regimen in ghana an observational longitudinal study |
| topic | Dolutegravir Type 2 diabetes mellitus Sub-Saharan Africa ART Cohort studies |
| url | https://doi.org/10.1186/s41043-024-00695-0 |
| work_keys_str_mv | AT margaretlartey incidenceoftype2diabetesmellitusinpersonslivingwithhivinitiatedondolutegravirbasedantiretroviralregimeninghanaanobservationallongitudinalstudy AT ernestkenu incidenceoftype2diabetesmellitusinpersonslivingwithhivinitiatedondolutegravirbasedantiretroviralregimeninghanaanobservationallongitudinalstudy AT vincentganu incidenceoftype2diabetesmellitusinpersonslivingwithhivinitiatedondolutegravirbasedantiretroviralregimeninghanaanobservationallongitudinalstudy AT stephenayisiaddo incidenceoftype2diabetesmellitusinpersonslivingwithhivinitiatedondolutegravirbasedantiretroviralregimeninghanaanobservationallongitudinalstudy AT kofiagyabeng incidenceoftype2diabetesmellitusinpersonslivingwithhivinitiatedondolutegravirbasedantiretroviralregimeninghanaanobservationallongitudinalstudy AT deliabandoh incidenceoftype2diabetesmellitusinpersonslivingwithhivinitiatedondolutegravirbasedantiretroviralregimeninghanaanobservationallongitudinalstudy AT marijanatuabdulai incidenceoftype2diabetesmellitusinpersonslivingwithhivinitiatedondolutegravirbasedantiretroviralregimeninghanaanobservationallongitudinalstudy AT princetsekpetse incidenceoftype2diabetesmellitusinpersonslivingwithhivinitiatedondolutegravirbasedantiretroviralregimeninghanaanobservationallongitudinalstudy AT kwasitorpey incidenceoftype2diabetesmellitusinpersonslivingwithhivinitiatedondolutegravirbasedantiretroviralregimeninghanaanobservationallongitudinalstudy |